Research during the 1960s and 1970s into the possible use of cyclazocine for management of pain, and later for assisting treatment of narcotic addiction was severely hampered by the drug's psychotomimetic, dysphoric, and hallucinatory effects.<ref>{{ cite journal | url = http://jama.ama-assn.org/content/202/3/191.full.pdf | format = pdf | author = Freedman, A. M. | author2 = Fink, M. | author3 = Sharoff, R. | author4 = Zaks, A. | title = Cyclazocine and Methadone in Narcotic Addiction | journal = The Journal of the American Medical Association | year = 1967 | volume = 202 | issue = 3 | pages = 191â€“194 | doi = 10.1001/jama.1967.03130160065011 | pmid = 6072354 }}</ref> The [[dysphoria|dysphoric]]/[[anxiolytic|anxiety inducing]] effects the drug correlate with increasing dosage and would likely reduce the risk of abuse in the same manner as other opioids which preferentially act on the [[kappa opioid receptor|KOR]] versus the [[delta opioid receptor|DOR]]. and [[mu opioid receptor|MOR]], although the side-effect threshold is often lower than the lowest effective dose.
